3 Stocks Getting Rare Double Upgrades From Analysts

Market Overview - The market in 2025 is characterized by uncertainty driven by tariffs, interest rates, and inflation, presenting opportunities for investors with cash on the sidelines [1] - Analysts have adjusted their expectations post-earnings season, with some upgrading stocks they previously viewed as bearish, often leading to higher price targets [1][2] Advance Auto Parts (AAP) - Advance Auto Parts has a 12-month stock price forecast of $46.01, indicating an 11.88% downside from the current price of $52.21 [3] - Analysts are beginning to view AAP more favorably, with Redburn Partners upgrading the stock from Sell to Neutral and raising the price target from $28 to $45 due to strengthening fundamentals [4] - AAP is seen as a potential asymmetric play for investors, especially as competitors like AutoZone and O'Reilly are trading at historically high valuations [5] BioLineRx (BLRX) - BioLineRx has a 12-month stock price forecast of $26.00, suggesting a significant upside of 362.63% from the current price of $5.62 [6][7] - The stock was recently upgraded from Hold to Strong Buy by Jones Trading, driven by the completion of the transfer of U.S. commercial rights for its drug APHEXDA, allowing the company to focus on its oncology pipeline [8] - BioLineRx's equity stake in the partnership with Ayrmid Bio reduces cash burn risks while enabling milestone payments and royalties [9] Anheuser-Busch InBev (BUD) - Anheuser-Busch InBev has a 12-month stock price forecast of $71.50, indicating a slight upside of 0.68% from the current price of $71.02 [10] - Despite pressures from inflation and changing consumer habits, BUD's strong brand portfolio and growth in non-alcoholic beer categories are helping to boost sales [12] - Following a recent earnings report, BNP Paribas upgraded BUD from Hold to Strong Buy, highlighting the company's ability to beat earnings per share estimates despite a slight revenue miss [13]